Profile of the ProAxsis active neutrophil elastase immunoassay for precision medicine in chronic respiratory disease

References

• Hill AT, Campbell ERJ, Bayley DL, et al. Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with alpha(1)-antitrypsin deficiency (PiZ). Am J Respir Crit Care Med. 1999;160(6):1968–1975.
   PubMed Web of Science ®Google Scholar
• Stockley RA, Bayley D, Hill SL, et al. Assessment of airway neutrophils by sputum colour: correlation with airways inflammation. Thorax. 2001;56(5):366–372.
   PubMed Web of Science ®Google Scholar
• Sly PD, Gangell CL, Chen L, et al. Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med. 2013;368(21):1963–1970.
   PubMed Web of Science ®Google Scholar
• Fahy JV, Kim KW, Liu J, et al. Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. J Allergy Clin Immunol. 1995;95(4):843–852.
   PubMed Web of Science ®Google Scholar
• Miller BE, Tal-Singer R, Rennard SI, et al. Plasma fibrinogen qualification as a drug development tool in chronic obstructive pulmonary disease. Perspective of the chronic obstructive pulmonary disease biomarker qualification consortium. Am J Respir Crit Care Med. 2016 Mar 15;193(6):607–613.
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Hill AT. Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis. Mol Immunol. 2013;55(1):27–34.
   PubMed Web of Science ®Google Scholar
• Papayannopoulos V, Staab D, Zychlinsky A. Neutrophil elastase enhances sputum solubilization in cystic fibrosis patients receiving DNase therapy. PLoS One. 2011;6(12):e28526.
   PubMed Web of Science ®Google Scholar
• Gehrig S, Duerr J, Weitnauer M, et al. Lack of neutrophil elastase reduces inflammation, mucus hypersecretion, and emphysema, but not mucus obstruction, in mice with cystic fibrosis-like lung disease. Am J Respir Crit Care Med. 2014 May 1; 189(9):1082–1092.
   PubMed Web of Science ®Google Scholar
• Zabieglo K, Majewski P, Majchrzak-Gorecka M, et al. The inhibitory effect of secretory leukocyte protease inhibitor (SLPI) on formation of neutrophil extracellular traps. J Leukoc Biol. 2015 Jul;98(1):99–106.
   PubMed Web of Science ®Google Scholar
• Dubois AV, Gauthier A, Bréa D, et al. Influence of DNA on the activities and inhibition of neutrophil serine proteases in cystic fibrosis sputum. Am J Respir Cell Mol Biol. 2012 Jul;47(1):80–86.
   PubMed Web of Science ®Google Scholar
• Rabinovich RA, Miller BE, Wrobel K, et al. Circulating desmosine levels do not predict emphysema progression but are associated with cardiovascular risk and mortality in COPD. Eur Respir J. 2016 May;47(5):1365–1373.
   PubMed Web of Science ®Google Scholar
• Garratt LW, Sutanto EN, Ling KM, et al. Matrix metalloproteinase activation by free neutrophil elastase contributes to bronchiectasis progression in early cystic fibrosis. Eur Respir J. 2015 Aug;46(2):384–394.
   PubMed Web of Science ®Google Scholar
• Greulich T, Nell C, Hohmann D, et al. The prevalence of diagnosed α1-antitrypsin deficiency and its comorbidities: results from a large population-based database. Eur Respir J. 2017 Jan 4;49(1).
   PubMed Web of Science ®Google Scholar
• Limjunyawong N, Craig JM, Lagassé HA, et al. Experimental progressive emphysema in BALB/cJ mice as a model for chronic alveolar destruction in humans. Am J Physiol Lung Cell Mol Physiol. 2015 Oct 1;309(7):L662–76.
   PubMed Web of Science ®Google Scholar
• Berger M, Sorensen RU, Tosi MF, et al. Complement receptor expression on neutrophils at an inflammatory site, the Pseudomonas-infected lung in cystic fibrosis. J Clin Invest. 1989;84:1302–1313.
   PubMed Web of Science ®Google Scholar
• Tosi MF, Zakem H, Berger M. Neutrophil elastase cleaves C3bi on opsonized pseudomonas as well as CR1 on neutrophils to create a functionally important opsonin receptor mismatch. J Clin Invest. 1990;86:300–308.
   PubMed Web of Science ®Google Scholar
• Vandivier RW, Fadok VA, Hoffmann PR, et al. Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis. J Clin Invest. 2002;109:661–670.
   PubMed Web of Science ®Google Scholar
• Shao MX, Nadel JA. Neutrophil elastase induces MUC5AC mucin production in human airway epithelial cells via a cascade involving protein kinase C, reactive oxygen species, and TNF-alpha-converting enzyme. J Immunol. 2005 Sep 15;175(6):4009–4016.
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Smith MP, McHugh B, et al. Short and long term antibiotic therapy reduces airway and systemic inflammation in non-CF bronchiectasis. Am J Respir Crit Care Med. 2012;186(7):657–665.
   PubMed Web of Science ®Google Scholar
• Bartoli ML, Costa F, Malagrinò L, et al. Paggiaro P. Sputum inflammatory cells in COPD patients classified according to GOLD 2011 guidelines. Eur Respir J. 2016 Mar;47(3):978–980. DOI:10.1183/13993003.00784-2015
   PubMed Web of Science ®Google Scholar
• Wang Z, Bafadhel M, Haldar K, et al. Lung microbiome dynamics in COPD exacerbations. Eur Respir J. 2016 Apr;47(4):1082–1092.
   PubMed Web of Science ®Google Scholar
• Elborn JS, Bell SC, Madge SL, et al. Report of the European Respiratory Society/European Cystic Fibrosis Society Task Force on the care of adults with cystic fibrosis. Eur Respir J. 2016 Feb;47(2):420–428. DOI:10.1183/13993003.00592-2015.
   PubMed Web of Science ®Google Scholar
• Esther CR Jr, Turkovic L, Rosenow T, et al. Metabolomic biomarkers predictive of early structural lung disease in cystic fibrosis. Eur Respir J. 2016 Dec;48(6):1612–1621. DOI:10.1183/13993003.00524-2016
   PubMed Web of Science ®Google Scholar
• Stephenson AL, Tom M, Berthiaume Y, et al. A contemporary survival analysis of individuals with cystic fibrosis: a cohort study. Eur Respir J. 2015 Mar;45(3):670–679.
   PubMed Web of Science ®Google Scholar
• Burgel PR, Bellis G, Olesen HV, et al. Future trends in cystic fibrosis demography in 34 European countries. Eur Respir J. 2015 Jul;46(1):133–141.
   PubMed Web of Science ®Google Scholar
• Chassagnon G, Hubert D, Fajac I, et al. Long-term computed tomographic changes in cystic fibrosis patients treated with ivacaftor. Eur Respir J. 2016 Jul;48(1):249–252. DOI:10.1183/13993003.01918-2015. .
   PubMed Web of Science ®Google Scholar
• Dilokthornsakul P, Hansen RN, Campbell JD. Forecasting US ivacaftor outcomes and cost in cystic fibrosis patients with the G551D mutation. Eur Respir J. 2016 Jun;47(6):1697–1705. DOI:10.1183/13993003.01444-2015.
   PubMed Web of Science ®Google Scholar
• Ratjen F, Waters V, Klingel M, et al. Changes in airway inflammation during pulmonary exacerbations in patients with cystic fibrosis and primary ciliary dyskinesia. Eur Respir J. 2016 Mar;47(3):829–836. DOI:10.1183/13993003.01390-2015.
   PubMed Web of Science ®Google Scholar
• Muhlebach MS, Clancy JP, Heltshe SL, et al. Biomarkers for cystic fibrosis drug development. J Cyst Fibros. 2016 Nov;15(6):714–723.
   PubMed Web of Science ®Google Scholar
• McDonnell MJ, Aliberti S, Goeminne PC, et al. Multidimensional severity assessment in bronchiectasis- analysis of 7 European cohorts. Thorax 2016. in press.
   Web of Science ®Google Scholar
• McDonnell MJ, Goeminne PC, Restrepo MI, et al. Co-morbidities and the risk of mortality in patients with bronchiectasis. An international cohort study. Lancet Respir Med 2016 Dec;4(12):969–979.
   PubMed Web of Science ®Google Scholar
• Chalmers JD, McHugh BJ, Doherty CJ, et al. Mannose binding lectin deficiency and disease severity in non-CF bronchiectasis: a prospective study. Lancet Respir Med. 2013;1(3):175–274.
   PubMed Web of Science ®Google Scholar
• Quint JK, Millett ERC, Joshi M, et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: A population-based cohort study. Eur Respir J. 2016;47:186–193.
   PubMed Web of Science ®Google Scholar
• Ringshausen FC, de Roux A, Diel R, et al. Bronchiectasis in Germany: a population-based estimation of disease prevalence. Eur Respir J. 2015 Dec;46(6):1805–1807.
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Aliberti S, Polverino E, et al. The EMBARC European Bronchiectasis Registry: protocol for an international observational study. ERJ Open Res. Internet 2016;2:81-2015-81–2015. Available at: http://openres.ersjournals.com/content/2/1/00081-2015.
   PubMedGoogle Scholar
• Aliberti S, Masefield S, Polverino E, et al. Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration. Eur Respir J. 2016;48(3):632–647.
   PubMed Web of Science ®Google Scholar
• Finch S, McDonnell MJ, Abo-Leyah H, et al. A comprehensive analysis of the impact of Pseudomonas aeruginosa colonisation on prognosis in adult bronchiectasis. Ann Am Thorac Soc. 2015;12(11):1602–1611.
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Goemmine PC, Aliberti S, et al. The Bronchiectasis Severity Index: an international derivation and validation study. Am J Respir Crit Care Med. 2014;189(5):576–585.
   PubMed Web of Science ®Google Scholar
• Lonni S, Chalmers JD, Goeminne PC, et al. Etiology of non-cystic fibrosis bronchiectasis in adults and its relationship to severity. Ann Am Thorac Soc. 2015;12(12):1764–1770.
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Aliberti S, Blasi F. State of the art: management of bronchiectasis in adults. Eur Respir J. 2015;45(5):1446–1462.
   PubMed Web of Science ®Google Scholar
• Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): A randomised, double-blind, placebo-controlled trial. Lancet. 2012;380:660–667.
   PubMed Web of Science ®Google Scholar
• Sibila O, Suarez-Cuartin G, Rodrigo-Troyano A, et al. Secreted mucins and airway bacterial colonization in non-CF bronchiectasis. Respirology. 2016;20(7):1082–1088.
   Web of Science ®Google Scholar
• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 Report: GOLD Executive Summary. Eur Respir J. 2017 Mar 6;49(3):pii: 1700214.
   Web of Science ®Google Scholar
• Papi A, Saetta M, Fabbri L. Severe asthma: phenotyping to endotyping or vice versa? Eur Respir J. 2017 Feb 8;49(2):pii: 1700053.
   Web of Science ®Google Scholar
• Harrison M, Short PM, Williamson P, et al. Thrombocytosis is associated with increased short and long term mortality after exacerbation of chronic obstructive pulmonary disease: a role for anti-platelet therapy? Thorax. 2014;69(7):609–615.
   PubMed Web of Science ®Google Scholar
• Park HY, Wark PA, Wechsler ME. What is asthma-COPD overlap syndrome? Towards a consensus definition from a round table discussion. Eur Respir J. 2016 Sep;48(3):664–673.
   PubMed Web of Science ®Google Scholar
• Barnes NC, Sharma R, Lettis S, et al. Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. Eur Respir J. 2016 May;47(5):1374–1382.
   PubMed Web of Science ®Google Scholar
• Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J. 2016 Feb;47(2):410–419.
   PubMed Web of Science ®Google Scholar
• Huang JT, Bolton CE, Miller BE, et al. Age-dependent elastin degradation is enhanced in chronic obstructive pulmonary disease. Eur Respir J. 2016 Oct;48(4):1215–1218.
   PubMed Web of Science ®Google Scholar
• Pascoe SJ, Lipson DA, Locantore N, et al. A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol. Eur Respir J. 2016 Aug;48(2):320–330.
   PubMed Web of Science ®Google Scholar
• Kuo CS, Pavlidis S, Loza M, et al. T-helper cell type 2 (Th2) and non-Th2 molecular phenotypes of asthma using sputum transcriptomics in U-BIOPRED. Eur Respir J. 2017 Feb 8;49(2):pii: 1602135.
   Web of Science ®Google Scholar
• Chung KF. Neutrophilic asthma, a distinct target for treatment? Lancet Respir Med. 2016;4(10):765–767.
   PubMed Web of Science ®Google Scholar
• Mao B, Yang JW, Lu HW, et al. Asthma and bronchiectasis exacerbation. Eur Respir J. 2016 Jun;47(6):1680–1686.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Illing R, Hui CK, et al. Bacteria in sputum of stable severe asthma and increased airway wall thickness. Respir Res. 2012;13:35.
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, Metev H, Puu M, et al. Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2016 Aug 26 published online. DOI:10.1016/S2213-2600(16)30227-2.
   PubMed Web of Science ®Google Scholar
• Wenzel SE, Barnes PJ, Bleecker ER, et al. A randomized, double-blind, placebo- controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med. 2009;179:549–558.
   PubMed Web of Science ®Google Scholar
• Busse WW, Holgate S, Kerwin E, et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med. 2013;188:1294–1302.
   PubMed Web of Science ®Google Scholar
• Brusselle GG, VanderStichele C, Jordens P, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax. 2013;68:322–329.
   PubMed Web of Science ®Google Scholar
• Stockley R, De Soyza A, Gunawardena K, et al. Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis. Respir Med. 2013;107:524–533.
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, Aquino TO, O’Brien CD, et al. A randomised, placebo-controlled, dose-finding study of AZD9668, an oral inhibitor of neutrophil elastase, in patients with chronic obstructive pulmonary disease treated with tiotropium. Copd. 2012 Apr 9;(2):111–120.
   PubMedGoogle Scholar
• Han MK, Tayob N, Murray S, et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med. 2014 Jun 15;189(12):1503–1508.
   PubMed Web of Science ®Google Scholar
• Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009 Mar 5;360(10):973–984.
   PubMed Web of Science ®Google Scholar
• Korkmaz B, Attucci S, Epinette C, et al. Measurement of neutrophil elastase, proteinase-3 and cathepsin-G activities using intramolecularly quenched fluorogenic substrates. Methods Mol Biol. 2012;844:125–138.
   PubMedGoogle Scholar
• Moffitt KL, Walker B, McNally P, et al. Development of a novel ProteaseTag® activity immunoassay for the specific measurement of neutrophil elastase in clinical samples from patients with respiratory disease. Am J Respir Crit Care Med. 2016;193:A7425.
   Web of Science ®Google Scholar
• Mayer-Hamblett N, Aitken ML, Accurso FJ, et al. Association between pulmonary function and sputum biomarkers in cystic fibrosis. Am J Respir Crit Care Med. 2007;175(8):822–828.
   PubMed Web of Science ®Google Scholar
• Sagel SD, Wagner BD, Anthony MM, et al. Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis. Am J Respir Crit Care Med. 2012;186(9):857–865.
   PubMed Web of Science ®Google Scholar
• Sly PD, Gangell CL, Chen L, et al. Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med. 2013;368(21):1963–1970.
   PubMed Web of Science ®Google Scholar
• DeBoer EM, Swiercz W, Heltshe SL, et al. Automated CT scan scores of bronchiectasis and air trapping in cystic fibrosis. Chest. 2014;145(3):593–603.
   PubMed Web of Science ®Google Scholar
• Tsang KW, Chan K, Ho P, et al. Sputum elastase in steady-state bronchiectasis. Chest. 2000;117:420–426.
   PubMed Web of Science ®Google Scholar
• Goeminne PC, Vandooren J, Moelants EA, et al. The sputum colour chart as a predictor of lung inflammation, proteolysis and damage in non-cystic fibrosis bronchiectasis: a case-control analysis. Respirology (Carlton, Vic). 2014;19:203–210.
   PubMed Web of Science ®Google Scholar
• Aliberti S, Lonni S, Dore S, et al. Clinical phenotypes in adult patients with bronchiectasis. Eur Respir J. 2016;47(4):1113–1122.
   PubMed Web of Science ®Google Scholar
• Paone G, Conti V, Vestri A, et al. Analysis of sputum markers in the evaluation of lung inflammation and functional impairment in symptomatic smokers and COPD patients. Dis Markers. 2011;31(2):91–100.
   PubMed Web of Science ®Google Scholar
• Ilumets H, Rytilä PH, Sovijärvi AR, et al. Transient elevation of neutrophil proteinases in induced sputum during COPD exacerbation. Scand J Clin Lab Invest. 2008;68(7):618–623.
   PubMed Web of Science ®Google Scholar
• Mallia P, Footitt J, Sotero R, et al. Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(11):1117–1124.
   PubMed Web of Science ®Google Scholar
• Stolz D, Leeming DJ, Kristensen JH, et al. Systemic biomarkers of collagen and elastin turnover are associated with clinically relevant outcomes in COPD. Chest. 2017 Jan;151(1):47–59. DOI:10.1016/j.chest.2016.08.1440.
   PubMed Web of Science ®Google Scholar
• Vignola AM, Bonanno A, Mirabella A, et al. Increased levels of elastase and alpha1-antitrypsin in sputum of asthmatic patients. Am J Respir Crit Care Med. 1998 Feb;157(2):505–511.
   PubMed Web of Science ®Google Scholar
• Martin SL, Moffitt KL, Elborn JS, et al. Development of a novel tool for the rapid detection of neutrophil elastase as a marker of inflammation with in the clinic. J Cyst Fibros. 2011;10(suppl 1):S46.
   Google Scholar
• Moffitt KL, McNally P, Linnane B, et al. Utilisation of a novel ProteaseTag® ™ activity immunoassay for the specific measurement of neutrophil elastase in BAL from children with cystic fibrosis. Pediatr Pulmonol. 2015;50(S41):266–267.
   Google Scholar
• Chalmers JD, Moffitt KL, Suarez-Cuartin G, et al. Neutrophil elastase activity is associated with exacerbations and lung function decline in bronchiectasis. Am J Respir Crit Care Med 2017. in press.
   Web of Science ®Google Scholar
• Thulborn S, Akram N, Mistry V, et al. S45 Evaluating the sensitivity and specificity of active neutrophil elastase as a biomarker for bacterial infection in subjects with COPD. Thorax 2016;71:A28.
   Google Scholar
• Moffitt KL, Walker B, Chalmers J, et al. P102 Development of a novel ProteaseTag® activity immunoassay for the specific detection of neutrophil elastase in patients with chronic obstructive pulmonary disease (COPD). Thorax 2015;70:A126-A127.
   Google Scholar
• Moffitt KL, McNally P, Linnane B, et al. Utilisation of a novel ProteaseTag® activity immunoassay for the specific measurement of neutrophil elastase in BAL from children with cystic fibrosis. Poster session presented at North American Cystic Fibrosis Conference, Phoenix, AZ, United States. 2015;226-227.
   Google Scholar
• Shaw DE, Sousa AR, Fowler SJ, et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J. 2015 Nov;46(5):1308–1321.
   PubMed Web of Science ®Google Scholar
• Mandal P, Chalmers JD, Graham C, et al. Atorvastatin as a stable treatment in bronchiectasis: a randomised controlled trial. Lancet Respir Med. 2014;2(6):455–463.
   PubMed Web of Science ®Google Scholar
• Barker AF, O’Donnell AE, Flume P, et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med. 2014;2:738–749.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Vogelmeier C, Roche N, et al. A review of national guidelines for management of COPD in Europe. Eur Respir J. 2016 Feb;47(2):625–637. DOI:10.1183/13993003.01170-2015. .
   PubMed Web of Science ®Google Scholar
• De Soyza A, Pavord I, Elborn JS, et al. A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis. Eur Respir J. 2015 Oct;46(4):1021–1032.
   PubMed Web of Science ®Google Scholar
• Haworth CS, Bilton D, Elborn JS. Long-term macrolide maintenance therapy in non-CF bronchiectasis: evidence and questions. Respir Med. 2014 Oct;108(10):1397–1408.
   PubMed Web of Science ®Google Scholar
• Sapey E, Greenwood H, Walton G, et al. Phosphoinositide 3-kinase inhibition restores neutrophil accuracy in the elderly: toward targeted treatments for immunosenescence. Blood. 2014;123(2):239–248.
   PubMed Web of Science ®Google Scholar
• Laine DI, Busch-Petersen J. Inhibitors of cathepsin C (dipeptidyl peptidase I). Expert Opin Ther Pat. 2010 Apr;20(4):497–506.
   PubMed Web of Science ®Google Scholar